Jump to content

PR-000608

Add links
From Wikipedia, the free encyclopedia

PR-608
Clinical data
Other namesPR 000608
Identifiers
  • 1-(4,4-Bis(4-fluorophenyl)butyl)-4-(2-hydroxy-3-phenylaminopropyl)piperazine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC29H35F2N3
Molar mass463.617 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(CNC4=CC=CC=C4)O
  • InChI=1S/C29H35F2N3O/c30-25-12-8-23(9-13-25)29(24-10-14-26(31)15-11-24)7-4-16-33-17-19-34(20-18-33)22-28(35)21-32-27-5-2-1-3-6-27/h1-3,5-6,8-15,28-29,32,35H,4,7,16-22H2
  • Key:YIBOKAQCZWKXIM-UHFFFAOYSA-N

PR-608 is a potent dopamine reuptake inhibitor related to vanoxerine. However, the GBR class of agents was known to be derived from diphenhydramine (or more specifically flunamine) as exemplified by S-350 and bears the distinctive benzhydryl ether functional group.[1][2] PR-608 on the other hand belongs to the structurally distinct diphenylbutylpiperazine class of agents (related to the diphenylbutylpiperidine class). Other members of this class include amperozide, lidoflazine, difluanazine,[3][4] FG5865 and FG-5893.[5]

PR-608 has been shown in preclinical studies to inhibit dopamine uptake in the central nervous system and may have potential applications in neuropsychiatric and cardiovascular disorders.[6][7][8][9]

The calcium channel blocking properties of PR-608 might make it useful as a cardiac stimulant for the treatment of heart disease or as a cerebral vasodilator.[10] Alternative applications of this agent include for the treatment of psychostimulant addiction, neurodegenerative diseases including (but not limited to) Parkinson's disease,[11][12] and as a treatment for depression.[13][14][15] Since dopamine regulates the appetite, PR-608 might also find use for treating binge eating disorder (BED) as well as treating narcolepsy.

See also

[edit]

References

[edit]
  1. ^ Buzas, A., Champagnac, A., Dehnel, A., Lavielle, G., Pommier, M. (February 1980). "Synthesis and psychoanaleptic properties of new compounds structurally related to diphenhydramine". Journal of Me-dicinal Chemistry. 23 (2): 149–153. doi:10.1021/jm00176a009.
  2. ^ Buzas, A., Champagnac, A., Dehnel, A., Lavielle, G., Pommier, M. (1 July 1980). "ChemInform Ab-stract: SYNTHESIS AND PSYCHOANALEPTIC PROPERTIES OF NEW COMPOUNDS STRUCTUR-ALLY RELATED TO DIPHENHYDRAMINE". Chemischer Informationsdienst. 11 (26). doi:10.1002/chin.198026225.
  3. ^ "Difluanazine". PubChem. U.S. National Library of Medicine.
  4. ^ US 3267104, Hermans HK, Karl-Adolf SW, "1,4-Disubstituted piperazines and diazepines", issued 16 August 1966, assigned to Janssen Pharmaceutica NV 
  5. ^ Hjorth, S., Pettersson, G. (July 1993). "5-HT1A autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo". European Journal of Pharmacology. 238 (2–3): 357–367. doi:10.1016/0014-2999(93)90867-H.
  6. ^ Kimura M, Masuda T, Yamada K, Mitani M, Kubota N, Kawakatsu N, et al. (April 2003). "Syntheses of novel diphenyl piperazine derivatives and their activities as inhibitors of dopamine uptake in the central nervous system". Bioorganic & Medicinal Chemistry. 11 (8): 1621–1630. doi:10.1016/s0968-0896(03)00061-0. PMID 12659747.
  7. ^ Kimura M, Masuda T, Yamada K, Mitani M, Kubota N, Kawakatsu N, et al. (September 2003). "Novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter". Bioorganic & Medicinal Chemistry. 11 (18): 3953–3963. doi:10.1016/s0968-0896(03)00428-0. PMID 12927856.
  8. ^ Kimura M, Masuda T, Yamada K, Mitani M, Kubota N, Kawakatsu N, et al. (June 2004). "Efficient asymmetric syntheses, determination of absolute configurations and biological activities of 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-hydroxy-3-(phenylamino)propyl]piperazine as a novel potent dopamine uptake inhibitor in the central nervous system". Bioorganic & Medicinal Chemistry. 12 (11): 3069–3078. doi:10.1016/j.bmc.2004.02.041. PMID 15142566.
  9. ^ US 5391552, Inazu M, Miyata Y, Morimoto T, Yamamoto T, Yoshiko Y, Harada K, Momota Y, Yanagi M, Yokota R, Katoh T, Namiki T, Kimura M, Kawakatsu N, "Diphenylpiperazine derivative and drug for circulatory organ containing the same.", issued 21 February 1995, assigned to Pola Orbis Holdings Inc. 
  10. ^ Kimura M, Masuda T, Yamada K, Kubota N, Kawakatsu N, Mitani M, et al. (August 2002). "Novel diphenylalkyl piperazine derivatives with dual calcium antagonistic and antioxidative activities". Bioorganic & Medicinal Chemistry Letters. 12 (15): 1947–1950. doi:10.1016/s0960-894x(02)00322-0. PMID 12113815.
  11. ^ "PR-000608". PatSnap.
  12. ^ Harada M, Kubota N, Masuda T, Inazu M (January 1996). "P-525: Effects of PR-000608, a novel antiparkinson drug, on MPTP-induced parkinsonism". Japanese Journal of Pharmacology. 71: 190. doi:10.1016/S0021-5198(19)36998-7.
  13. ^ Orr K, Taylor D (2007). "Psychostimulants in the treatment of depression : a review of the evidence". CNS Drugs. 21 (3): 239–57. doi:10.2165/00023210-200721030-00004. PMID 17338594.
  14. ^ Dunlop BW, Nemeroff CB (March 2007). "The role of dopamine in the pathophysiology of depression". Archives of General Psychiatry. 64 (3): 327–37. doi:10.1001/archpsyc.64.3.327. PMID 17339521.
  15. ^ Gershon AA, Vishne T, Grunhaus L (January 2007). "Dopamine D2-like receptors and the antidepressant response". Biological Psychiatry. 61 (2): 145–53. doi:10.1016/j.biopsych.2006.05.031. PMID 16934770.
Retrieved from "https://en.wikipedia.org/w/index.php?title=PR-000608&oldid=1294040430"